BioXcel Therapeutics, Inc. (BTAI) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1246626,
    "name": "BioXcel Therapeutics, Inc.",
    "stock_name": "BioXcel Therapeutics, Inc.",
    "full_name": "BioXcel Therapeutics, Inc.",
    "name_url": "stocks-analysis/bioxcel-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.09",
    "chg": 0.22,
    "chgp": "11.76%",
    "dir": 1,
    "prev_price": "1.87",
    "mcapval": "61.58",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US09075P1057",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "927.37 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bioxcel-therapeutics-inc-1246626-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is BioXcel Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bioxcel-therapeutics-inc-technically-bullish-or-bearish-3547820",
        "imagepath": "",
        "date": "2025-09-20 20:03:48",
        "description": "As of 9 September 2025, the technical trend for BioXcel Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is also mildly bullish, indicating some mixed signals. The daily moving averages are mildly bullish, while the weekly Dow Theory shows a mildly bearish stance. The Bollinger Bands present a mildly bullish signal on the weekly but bearish on the monthly, and the KST is bullish weekly but only mildly bullish monthly. The OBV is mildly bearish on the weekly timeframe.\n\nIn terms of performance, BioXcel has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -49.69% versus the S&P 500's 12.22%, and a one-year return of -70.48% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by the mixed indicators and significant underperformance relative t..."
      },
      {
        "title": "Is BioXcel Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bioxcel-therapeutics-inc-overvalued-or-undervalued-3544072",
        "imagepath": "",
        "date": "2025-09-20 18:36:53",
        "description": "As of 12 August 2025, the valuation grade for BioXcel Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is overvalued given its current metrics, particularly with a Price to Book Value of -0.12, an EV to EBIT of -1.74, and an EV to EBITDA of -1.75, all of which suggest severe financial distress and negative returns on capital employed. \n\nIn comparison to its peers, C4 Therapeutics, Inc. has a P/E of -1.7285 and an EV to EBITDA of 0.1350, while Champions Oncology, Inc. stands out with a very attractive P/E of 19.9287 and an EV to EBITDA of 13.1831, highlighting how BioXcel's metrics fall short against more stable companies in the sector. Additionally, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -49.69% compared to the index's gain of 12.22%, reinforcing the noti..."
      }
    ],
    "total": 7,
    "sid": "1246626",
    "stock_news_url": "https://www.marketsmojo.com/news/bioxcel-therapeutics-inc-1246626"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is BioXcel Therapeutics, Inc. technically bullish or bearish?

2025-09-20 20:03:48

As of 9 September 2025, the technical trend for BioXcel Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is also mildly bullish, indicating some mixed signals. The daily moving averages are mildly bullish, while the weekly Dow Theory shows a mildly bearish stance. The Bollinger Bands present a mildly bullish signal on the weekly but bearish on the monthly, and the KST is bullish weekly but only mildly bullish monthly. The OBV is mildly bearish on the weekly timeframe. In terms of performance, BioXcel has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -49.69% versus the S&P 500's 12.22%, and a one-year return of -70.48% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by the mixed indicators and significant underperformance relative t...

Is BioXcel Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:36:53

As of 12 August 2025, the valuation grade for BioXcel Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is overvalued given its current metrics, particularly with a Price to Book Value of -0.12, an EV to EBIT of -1.74, and an EV to EBITDA of -1.75, all of which suggest severe financial distress and negative returns on capital employed. In comparison to its peers, C4 Therapeutics, Inc. has a P/E of -1.7285 and an EV to EBITDA of 0.1350, while Champions Oncology, Inc. stands out with a very attractive P/E of 19.9287 and an EV to EBITDA of 13.1831, highlighting how BioXcel's metrics fall short against more stable companies in the sector. Additionally, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -49.69% compared to the index's gain of 12.22%, reinforcing the noti...

View All News